South Sudan

South Sudan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
6.49 (5.20 - 8.07) 2019 Modelled IHME
7.12 (5.78 - 8.68) 2018 Modelled IHME
7.38 (5.94 - 8.93) 2017 Modelled IHME
7.24 (5.81 - 8.77) 2016 Modelled IHME
7.1 (5.65 - 8.70) 2015 Modelled IHME
7.16 (5.68 - 8.78) 2014 Modelled IHME
7.29 (5.76 - 8.96) 2013 Modelled IHME
7.46 (5.85 - 9.19) 2012 Modelled IHME
7.6 (5.92 - 9.41) 2011 Modelled IHME
7.66 (5.97 - 9.45) 2010 Modelled IHME
7.66 (5.99 - 9.41) 2009 Modelled IHME
7.65 (6.03 - 9.30) 2008 Modelled IHME
7.64 (6.02 - 9.27) 2007 Modelled IHME
7.63 (6.03 - 9.28) 2006 Modelled IHME
7.63 (6.02 - 9.31) 2005 Modelled IHME
7.64 (6.07 - 9.25) 2004 Modelled IHME
7.65 (6.10 - 9.28) 2003 Modelled IHME
7.68 (6.12 - 9.36) 2002 Modelled IHME
7.7 (6.14 - 9.46) 2001 Modelled IHME
7.72 (6.15 - 9.62) 2000 Modelled IHME
7.74 (6.18 - 9.58) 1999 Modelled IHME
7.76 (6.15 - 9.57) 1998 Modelled IHME
7.79 (6.14 - 9.61) 1997 Modelled IHME
7.82 (6.11 - 9.64) 1996 Modelled IHME
7.85 (6.04 - 9.69) 1995 Modelled IHME
7.89 (6.11 - 9.70) 1994 Modelled IHME
7.93 (6.21 - 9.71) 1993 Modelled IHME
7.98 (6.28 - 9.73) 1992 Modelled IHME
8.04 (6.33 - 9.78) 1991 Modelled IHME
8.1 (6.42 - 9.86) 1990 Modelled IHME
22.16 (17.98 - 26.63) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
2.56 (1.87 - 3.41) 2019 Modelled IHME
3.22 (2.40 - 4.12) 2018 Modelled IHME
3.48 (2.58 - 4.49) 2017 Modelled IHME
3.25 (2.39 - 4.25) 2016 Modelled IHME
3.03 (2.16 - 4.04) 2015 Modelled IHME
3.29 (2.38 - 4.37) 2014 Modelled IHME
3.92 (2.79 - 5.22) 2013 Modelled IHME
4.68 (3.30 - 6.24) 2012 Modelled IHME
5.32 (3.74 - 7.10) 2011 Modelled IHME
5.58 (3.93 - 7.53) 2010 Modelled IHME
5.58 (3.96 - 7.38) 2009 Modelled IHME
5.56 (4.02 - 7.29) 2008 Modelled IHME
5.54 (4.07 - 7.27) 2007 Modelled IHME
5.52 (4.08 - 7.26) 2006 Modelled IHME
5.51 (3.97 - 7.25) 2005 Modelled IHME
5.52 (4.04 - 7.23) 2004 Modelled IHME
5.55 (4.07 - 7.30) 2003 Modelled IHME
5.58 (4.05 - 7.43) 2002 Modelled IHME
5.61 (4.08 - 7.54) 2001 Modelled IHME
5.63 (4.06 - 7.64) 2000 Modelled IHME
5.65 (4.12 - 7.60) 1999 Modelled IHME
5.66 (4.12 - 7.57) 1998 Modelled IHME
5.67 (4.12 - 7.55) 1997 Modelled IHME
5.69 (4.08 - 7.50) 1996 Modelled IHME
5.71 (4.07 - 7.61) 1995 Modelled IHME
5.73 (4.13 - 7.57) 1994 Modelled IHME
5.75 (4.13 - 7.58) 1993 Modelled IHME
5.78 (4.23 - 7.58) 1992 Modelled IHME
5.81 (4.24 - 7.56) 1991 Modelled IHME
5.84 (4.21 - 7.62) 1990 Modelled IHME
21.13 (16.74 - 26.21) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
33 (25 - 42) 2019 Modelled IHME
33 (25 - 42) 2018 Modelled IHME
33 (25 - 41) 2017 Modelled IHME
33 (25 - 42) 2016 Modelled IHME
33 (25 - 41) 2015 Modelled IHME
33 (25 - 41) 2014 Modelled IHME
33 (25 - 41) 2013 Modelled IHME
32 (25 - 41) 2012 Modelled IHME
32 (25 - 41) 2011 Modelled IHME
32 (24 - 41) 2010 Modelled IHME
32 (25 - 41) 2009 Modelled IHME
32 (24 - 41) 2008 Modelled IHME
32 (24 - 41) 2007 Modelled IHME
32 (24 - 41) 2006 Modelled IHME
32 (24 - 41) 2005 Modelled IHME
32 (24 - 41) 2004 Modelled IHME
32 (24 - 40) 2003 Modelled IHME
31 (24 - 40) 2002 Modelled IHME
31 (24 - 40) 2001 Modelled IHME
32 (24 - 40) 2000 Modelled IHME
32 (24 - 40) 1999 Modelled IHME
32 (24 - 40) 1998 Modelled IHME
32 (24 - 41) 1997 Modelled IHME
32 (24 - 41) 1996 Modelled IHME
32 (24 - 41) 1995 Modelled IHME
32 (24 - 41) 1994 Modelled IHME
32 (24 - 41) 1993 Modelled IHME
32 (24 - 41) 1992 Modelled IHME
32 (24 - 41) 1991 Modelled IHME
32 (24 - 41) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
49 2018 Survey/reported WHO/UNICEF
47 2017 Survey/reported WHO/UNICEF
45 2016 Survey/reported WHO/UNICEF
31 2015 Survey/reported WHO/UNICEF
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV elimination goal
HCV elimination goal
Eligible for HCV generic medicines

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.42 (1.14 - 1.78) 2019 Modelled IHME
1.44 (1.15 - 1.81) 2018 Modelled IHME
1.44 (1.15 - 1.81) 2017 Modelled IHME
1.43 (1.16 - 1.77) 2016 Modelled IHME
1.41 (1.15 - 1.75) 2015 Modelled IHME
1.42 (1.15 - 1.76) 2014 Modelled IHME
1.42 (1.15 - 1.76) 2013 Modelled IHME
1.43 (1.16 - 1.77) 2012 Modelled IHME
1.43 (1.16 - 1.78) 2011 Modelled IHME
1.44 (1.15 - 1.80) 2010 Modelled IHME
1.45 (1.16 - 1.81) 2009 Modelled IHME
1.46 (1.17 - 1.82) 2008 Modelled IHME
1.47 (1.18 - 1.83) 2007 Modelled IHME
1.48 (1.19 - 1.85) 2006 Modelled IHME
1.5 (1.20 - 1.86) 2005 Modelled IHME
1.51 (1.21 - 1.88) 2004 Modelled IHME
1.52 (1.22 - 1.90) 2003 Modelled IHME
1.53 (1.22 - 1.91) 2002 Modelled IHME
1.54 (1.23 - 1.94) 2001 Modelled IHME
1.55 (1.24 - 1.95) 2000 Modelled IHME
1.55 (1.24 - 1.96) 1999 Modelled IHME
1.56 (1.25 - 1.96) 1998 Modelled IHME
1.57 (1.26 - 1.97) 1997 Modelled IHME
1.58 (1.26 - 1.97) 1996 Modelled IHME
1.58 (1.27 - 1.98) 1995 Modelled IHME
1.59 (1.28 - 1.99) 1994 Modelled IHME
1.6 (1.29 - 2) 1993 Modelled IHME
1.61 (1.30 - 2.02) 1992 Modelled IHME
1.63 (1.31 - 2.04) 1991 Modelled IHME
1.64 (1.31 - 2.06) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
22 (15 - 29) 2019 Modelled IHME
22 (15 - 29) 2018 Modelled IHME
22 (15 - 29) 2017 Modelled IHME
21 (15 - 28) 2016 Modelled IHME
21 (15 - 28) 2015 Modelled IHME
21 (14 - 27) 2014 Modelled IHME
21 (14 - 27) 2013 Modelled IHME
21 (14 - 27) 2012 Modelled IHME
21 (14 - 27) 2011 Modelled IHME
21 (14 - 27) 2010 Modelled IHME
21 (14 - 27) 2009 Modelled IHME
21 (14 - 27) 2008 Modelled IHME
21 (14 - 28) 2007 Modelled IHME
21 (14 - 28) 2006 Modelled IHME
21 (15 - 28) 2005 Modelled IHME
21 (15 - 28) 2004 Modelled IHME
21 (15 - 28) 2003 Modelled IHME
21 (15 - 29) 2002 Modelled IHME
21 (15 - 28) 2001 Modelled IHME
21 (15 - 28) 2000 Modelled IHME
21 (15 - 28) 1999 Modelled IHME
21 (15 - 28) 1998 Modelled IHME
21 (15 - 28) 1997 Modelled IHME
21 (15 - 28) 1996 Modelled IHME
21 (15 - 28) 1995 Modelled IHME
21 (15 - 28) 1994 Modelled IHME
21 (15 - 28) 1993 Modelled IHME
21 (15 - 29) 1992 Modelled IHME
21 (15 - 29) 1991 Modelled IHME
21 (15 - 29) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV elimination goal
HCV elimination goal
Eligible for HCV generic medicines

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
6.49 (%)
2019
(5.2 - 8.07(%))
IHME
HCV (RNA/cAg+)
1.42 (%)
2019
(1.14 - 1.78(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
541
2019
(327 - 865)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
580
2019
(358 - 873)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
2.56 (%)
2019, latest modelled
(1.87 - 3.41(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines